EDIT
Editas Medicine, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website editasmedicine.com
- Employees(FY) 226
- ISIN US28106W1036
Performance
+1.08%
1W
-3.93%
1M
-31.04%
3M
-35.99%
6M
-44.52%
YTD
-41.52%
1Y
Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Investment Analysis Report: Edit (EDIT)
Overview:
Edit (EDIT) operates in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $665.64 million. In this report, we will conduct a comprehensive analysis of Edit's financial statements over the past three years, focusing on the Balance ...
Technical Analysis of EDIT 2024-05-10
Overview:
In analyzing the technical indicators for EDIT stock over the last 5 days, we will delve into the trends, momentum, volatility, and volume aspects to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining key indicators such as moving averages, MACD, RSI, Bollinger Bands, and OBV, we aim t...
Recent News & Updates
- 2024-05-14 19:01
- 2024-05-14 16:27
- 2024-05-14 10:00
- 2024-05-13 22:00
- 2024-05-12 08:00
- 2024-05-10 06:00
- 2024-05-09 18:00
- 2024-05-09 15:38
- 2024-05-09 13:12
- 2024-05-09 12:40
- 2024-05-09 11:33
- 2024-05-09 06:26
Editas Medicine First Quarter 2024 Earnings: Misses Expectations(Simply Wall St.)
- 2024-05-09 03:38
- 2024-05-09 00:40
- 2024-05-08 20:00
- 2024-05-08 10:33
Q1 2024 Editas Medicine Inc Earnings Call(Yahoo Finance)
- 2024-05-08 07:29
Editas: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-08 07:00
- 2024-05-07 23:55
- 2024-05-07 20:25
- 2024-05-07 19:00
- 2024-05-05 09:14
- 2024-05-02 07:00
- 2024-05-01 19:00
- 2024-05-01 10:46
- 2024-05-01 08:00
- 2024-04-30 20:00
- 2024-04-29 10:26
12 Under-the-Radar Stocks With Massive Upside for 2024(Insider Monkey)
- 2024-04-28 22:26
12 Under-the-Radar Stocks With Massive Upside for 2024(Insidermonkey)
- 2024-04-26 10:00
Page 1 of 6
previousnext